Efficacy and Safety Results With Rilzabrutinib, an Oral Bruton Tyrosine Kinase Inhibitor, in Patients With Immune Thrombocytopenia: Phase 2 Part B Study
American Journal of Hematology · 2025-03 · 100 (3) · 439-449
DOI: 10.1002/ajh.27539 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift American Journal of Hematology, online erschienen am 22.01.2025. Verfasst von Nichola Cooper und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department Immunology and Inflammation, Imperial College, Hammersmith Hospital, London, UK. Hauptthemen laut MEDLINE: Purpura, Thrombocytopenic, Idiopathic, Agammaglobulinaemia Tyrosine Kinase, Protein Kinase Inhibitors, Pyrimidines. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Sanofi.
Abstract (Originalsprache)
Current treatments for persistent or chronic immune thrombocytopenia (ITP) are limited by inadequate response, toxicity, and impaired quality of life. The Bruton tyrosine kinase inhibitor rilzabrutinib was evaluated to further characterize safety and durability of platelet response. LUNA2 Part B is a multicenter, phase 1/2 study in adults with ITP (≥ 3 months duration, platelet count < 30 × 10 9 /L) who failed ≥ 1 ITP therapy (NCT03395210, EudraCT 2017–004012‐19). Oral rilzabrutinib 400 mg bid was given over 24 weeks, with optional long‐term extension (LTE). Primary endpoints were safety and platelet counts ≥ 50 × 10 9 /L on ≥ 8 of the last 12 weeks of main treatment without rescue medication. From 22 March2018 to 31 January2023, 26 patients were enrolled. Patients had baseline median platelet count 13 × 10 9 /L, ITP duration 10.3 years, and six prior ITP therapies (46% splenectomized). Nine (35%) patients achieved the primary endpoint. Platelet counts ≥ 50 × 10 9 /L or ≥ 30 × 10 9 /L and doubling from baseline without rescue therapy were sustained for a mean 9.3 weeks. 11 (42%) LTE‐eligible patients were ongoing with median LTE platelet > 80 × 10 9 /L. Three (12%) patients received rescue medication during main treatment, none in LTE. Clinically meaningful improvements were observed in fatigue and women's health. With a median treatment duration of 167 days (main treatment), 16 (62%) patients had ≥ 1 treatment‐related adverse event (AE), mainly grade 1, including diarrhea (35%), headache (23%), and nausea (15%). There was no treatment‐related grade ≥ 2 bleeding/thrombotic events/infections, serious AE, or death. Rilzabrutinib continues to demonstrate durable platelet responses with favorable safety profile in previously treated ITP patients. Trial Registration: NCT03395210, EudraCT 2017‐004012‐19
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department Immunology and Inflammation, Imperial College, Hammersmith Hospital, London, UK.
- Erasmus MC, University Medical Center, Rotterdam, The Netherlands.
- Princess Alexandra Hospital, Woolloongabba, Australia.
- Masaryk University Hospital, Brno, Czech Republic.
- St. Michael's Hospital, Li Ka Shing Knowledge Institute, University of Toronto, Toronto, Ontario, Canada.
- The Bleeding and Clotting Disorders Institute, University of Illinois College of Medicine-Peoria, Peoria, Illinois, USA.
ORCID-Profile: Nichola Cooper, A J Gerard Jansen, Robert Bird, Jiří Mayer, Michelle Sholzberg, Michael D Tarantino, Mamta Garg, Paula F Ypma, Vickie McDonald, Milan Košťál, Terry B Gernsheimer, Remco Diab, Ahmed Daak, David J Kuter
Förderung
- Sanofi
Zitieren
APA
Cooper, N., Jansen, A. J. G., Bird, R., Mayer, J., Sholzberg, M., Tarantino, M. D., Garg, M., Ypma, P. F., McDonald, V., Percy, C., Košťál, M., Goncalves, I., Bogdanov, L. H., Gernsheimer, T. B., Diab, R., Yao, M., Daak, A., & Kuter, D. J. (2025). Efficacy and Safety Results With Rilzabrutinib, an Oral Bruton Tyrosine Kinase Inhibitor, in Patients With Immune Thrombocytopenia: Phase 2 Part B Study. American Journal of Hematology, 100(3), 439-449. https://doi.org/10.1002/ajh.27539
Vancouver
Cooper N, Jansen AJG, Bird R, Mayer J, Sholzberg M, Tarantino MD, et al. Efficacy and Safety Results With Rilzabrutinib, an Oral Bruton Tyrosine Kinase Inhibitor, in Patients With Immune Thrombocytopenia: Phase 2 Part B Study. American Journal of Hematology. 2025;100(3):439-449. doi:10.1002/ajh.27539
BibTeX
@article{Cooper2025,
author = {Cooper, Nichola and Jansen, A J Gerard and Bird, Robert and Mayer, Jiří and Sholzberg, Michelle and Tarantino, Michael D and Garg, Mamta and Ypma, Paula F and McDonald, Vickie and Percy, Charles and Košťál, Milan and Goncalves, Isaac and Bogdanov, Lachezar H and Gernsheimer, Terry B and Diab, Remco and Yao, Mengjie and Daak, Ahmed and Kuter, David J},
title = {Efficacy and Safety Results With Rilzabrutinib, an Oral Bruton Tyrosine Kinase Inhibitor, in Patients With Immune Thrombocytopenia: Phase 2 Part B Study},
journal = {American Journal of Hematology},
year = {2025},
volume = {100},
number = {3},
pages = {439--449},
doi = {10.1002/ajh.27539}
}
EUVIMED